A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS

NCT01085656 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Leukemia, Myelogenous, Acute
Myelodysplastic Syndromes

Interventions

DRUG: OXi4503

Sponsor

University of Florida

Collaborators

[object Object]